CRWE NewsWire

Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, recently announced that one of its proprietary confectionary over-the-counter products, Glucose RapidSpray, is now available under a trial run at selected Boots UK retail chain stores.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device.

Power3 Medical Products, Inc. (OTCBB: PWRM.OB) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

Power 3 Medical Products, Inc. is a biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company’s proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease.

Tamir Biotechnology, Inc. (OTCBB:ACEL.OB), (formerly known as Alfacell Corporation), a biopharmaceutical company focused on the discovery, development, and commercialization of novel ribonuclease (RNase) therapeutics for cancer and virology, today announced that Tommy G. Thompson, former Secretary of the U.S. Department of Health and Human Services and four-term Governor of Wisconsin, has rejoined the company as a Special Advisor to Chief Executive Officer Charles Muniz and will also be the Chairman of its Oncology and Anti-Viral Business Development Advisory Committee.

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.read more Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).